Radiopharmaceutical specialist G-SURE (7762) is set to list on the Emerging Stock Board on the 25th. The management team noted that sales of existing products remain steady, and the company is well-positioned for stable growth throughout this year and next.
G-SURE: 13 years of nuclear medicine expertise since 2011; land in Zhunan acquired for the construction of a second plant.
According to the Taipei Exchange, HappyTuk (7584) will officially list on the TPEx market between July 22 and July 26, 2024.
G-SURE stated that it has accumulated 13 years of experience in radiopharmaceutical manufacturing since 2011. By optimizing production capacity, upgrading equipment, implementing international pharmaceutical operational control systems, cultivating specialized talent, and enhancing professional logi
Operating from midnight until noon to accommodate the unique nature of its products, G-SURE is set to become the first specialized nuclear medicine pharmaceutical firm to list in Taiwan. The company expects to register on the Emerging Stock Board on July 25 at a reference price of NT$28.
G-SURE (7762-TW) Investor Update: Pre-IPO conference on Jan 23, with Emerging Stock Board debut on Jan 25 (Ref. Price: NT$28). As the only radiopharma firm with dual certification from MOHW and NSC, G-SURE marks a historic milestone as the first nuclear medicine specialist to enter Taiwan’s capital.
G-SURE General Manager Lin Liang-kuang stated that the company's primary growth drivers this year are FDG, a PET tracer for whole-body or localized imaging, and FBB, a brain PET imaging agent used for Alzheimer’s disease assessment. Due to full capacity at its existing facilities...
G-SURE Biotech (7762-TW) is set to list on the Emerging Stock Board on July 25. The company holds the distinction of being Taiwan's first radiopharmaceutical plant to receive dual certification from both the Ministry of Health and Welfare (MOHW) and the Nuclear Safety Commission (NSC).
G-SURE Chairman: With 6 TFDA licenses in oncology, we are expanding to a 2nd plant in Zhunan to focus on new isotopes and innovative drug production.